-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Short Interest Up 206.6% in January
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Short Interest Up 206.6% in January
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV – Get Rating) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 55,800 shares, an increase of 206.6% from the December 31st total of 18,200 shares. Approximately 3.1% of the shares of the company are sold short. Based on an average daily volume of 142,500 shares, the days-to-cover ratio is presently 0.4 days.
Analysts Set New Price Targets
Separately, StockNews.com initiated coverage on shares of BiondVax Pharmaceuticals in a research report on Tuesday. They issued a "sell" rating on the stock.
Get BiondVax Pharmaceuticals alerts:BiondVax Pharmaceuticals Price Performance
BVXV stock traded down $0.14 on Friday, reaching $2.61. 48,048 shares of the company were exchanged, compared to its average volume of 433,073. BiondVax Pharmaceuticals has a 12 month low of $2.37 and a 12 month high of $22.90. The stock's fifty day moving average price is $5.50 and its 200 day moving average price is $8.34. The company has a current ratio of 5.76, a quick ratio of 5.76 and a debt-to-equity ratio of 5.92.
BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) last announced its earnings results on Wednesday, November 30th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.16. As a group, equities analysts anticipate that BiondVax Pharmaceuticals will post -0.3 earnings per share for the current fiscal year.Hedge Funds Weigh In On BiondVax Pharmaceuticals
A hedge fund recently raised its stake in BiondVax Pharmaceuticals stock. Envestnet Asset Management Inc. increased its stake in shares of BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV – Get Rating) by 226.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 163,423 shares of the company's stock after acquiring an additional 113,418 shares during the quarter. Envestnet Asset Management Inc. owned about 1.44% of BiondVax Pharmaceuticals worth $191,000 at the end of the most recent reporting period.
BiondVax Pharmaceuticals Company Profile
(Get Rating)
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza.
Featured Stories
- Get a free copy of the StockNews.com research report on BiondVax Pharmaceuticals (BVXV)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV – Get Rating) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 55,800 shares, an increase of 206.6% from the December 31st total of 18,200 shares. Approximately 3.1% of the shares of the company are sold short. Based on an average daily volume of 142,500 shares, the days-to-cover ratio is presently 0.4 days.
BiondVax Pharmicals Ltd.(纳斯达克股票代码:BVXV — Get Rating)在1月份的空头利率大幅增加。截至1月15日,空头利率共计55,800股,较12月31日的18,200股增长了206.6%。该公司约有3.1%的股份被卖空。根据142,500股的平均每日成交量,目前天数与覆盖率为0.4天。
Analysts Set New Price Targets
分析师设定了新的价格目标
Separately, StockNews.com initiated coverage on shares of BiondVax Pharmaceuticals in a research report on Tuesday. They issued a "sell" rating on the stock.
另外,StockNews.com在周二的一份研究报告中开始报道BiondVax Pharmicals的股票。他们对该股发布了 “卖出” 评级。
BiondVax Pharmaceuticals Price Performance
BiondVax 制药价格表现
BVXV stock traded down $0.14 on Friday, reaching $2.61. 48,048 shares of the company were exchanged, compared to its average volume of 433,073. BiondVax Pharmaceuticals has a 12 month low of $2.37 and a 12 month high of $22.90. The stock's fifty day moving average price is $5.50 and its 200 day moving average price is $8.34. The company has a current ratio of 5.76, a quick ratio of 5.76 and a debt-to-equity ratio of 5.92.
周五,BVXV股票下跌0.14美元,至2.61美元。该公司交易了48,048股股票,而平均交易量为433,073股。BiondVax Pharmicals创下12个月低点2.37美元,12个月高点为22.90美元。该股的五十天移动平均价格为5.50美元,其200天移动平均线价格为8.34美元。该公司的流动比率为5.76,速动比率为5.76,债务与权益比率为5.92。
Hedge Funds Weigh In On BiondVax Pharmaceuticals
对冲基金对 BiondVax 制药进行权衡
A hedge fund recently raised its stake in BiondVax Pharmaceuticals stock. Envestnet Asset Management Inc. increased its stake in shares of BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV – Get Rating) by 226.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 163,423 shares of the company's stock after acquiring an additional 113,418 shares during the quarter. Envestnet Asset Management Inc. owned about 1.44% of BiondVax Pharmaceuticals worth $191,000 at the end of the most recent reporting period.
一家对冲基金最近提高了其在BiondVax Pharmicals股票中的股份。根据Envestnet Asset Management Inc.向美国证券交易委员会披露的最新信息,该公司在第二季度将其在BiondVax Pharmicals Ltd.(纳斯达克股票代码:BVXV — Get Ratinge)的股份增加了226.8%。该公司在本季度又收购了113,418股股票后,拥有该公司的163,423股股票。在最近的报告期结束时,Envestnet Asset Management Inc.拥有BiondVax Pharmicals约1.44%的股份,价值19.1万美元。
BiondVax Pharmaceuticals Company Profile
BiondVax 制药公司简介
(Get Rating)
(获取评分)
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza.
BiondVax Pharmicals Ltd.是一家临床阶段的生物制药公司,从事传染病免疫调节疗法的开发和商业化。它侧重于流感候选疫苗,该疫苗旨在提供针对季节性和大流行性流感的多菌株和多季节保护。
Featured Stories
精选故事
- Get a free copy of the StockNews.com research report on BiondVax Pharmaceuticals (BVXV)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免费获取 StockNews.com 关于 BiondVax Pharmicals (BVXV) 的研究报告的副本
- MarketBeat Week 回顾 — 1/23-1/27
- 为什么 Lucid 在一天之内飙升了近 100%
- 利用这些铁路股票实现增长和收入
- ASML 预计今年对芯片的需求将上涨,提振了销售前景
- KLA 公司:在陷入困境的半市场中的实力
Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收 BiondVax 制药日报的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收BiondVax Pharmicals及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧